In this video, Peter Black, MD, of the University of British Columbia, Vancouver, Canada, speaks to us about the use of biomarkers to identify bladder cancer patients eligible for neoadjuvant therapy. Dr Black discusses three types of biomarkers currently under investigation, covering molecular subtypes, the COXEN model and alterations in specific DNA damage repair genes. This interview was recorded at the 2018 Genitourinary Cancers Symposium in San Francisco, CA.
Using biomarkers to identify bladder cancer patients for neoadjuvant therapy
